PittsburghV1, Main, Exploration, bibRecord, 005D62

Preventing cancer by targeting abnormally expressed self‐antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas

Identifieur interne : 005D62 ( Main/Exploration ); précédent : 005D61; suivant : 005D63

Preventing cancer by targeting abnormally expressed self‐antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas

Auteurs : Pamela L. Beatty [États-Unis] ; Olivera J. Finn [États-Unis]

Source :

Annals of the New York Academy of Sciences [ 0077-8923 ] ; 2013-05.

RBID : ISTEX:D946B4FEC4126C746CBBFB89064A85A64A5C4123

Descripteurs français

Wicri :
- topic : Vaccin.

English descriptors

Abstract

Prophylactic vaccines based on tumor‐associated antigens (TAAs) have elicited concerns due to their potential toxicity. Because TAAs are considered self‐antigens, the prediction is that such vaccines will induce autoimmunity. While this has been observed in melanoma, where an antitumor immune response leads to vitiligo, autoimmunity has almost never been seen following vaccination with numerous other TAAs. We hypothesized that antigen choice determines outcome and have been working to identify TAAs whose expression differs between normal and tumor tissue, and thus could elicit antitumor immunity without autoimmunity. Studies on the epithelial TAA MUC1 have revealed that, compared to MUC1 on normal cells, tumors, premalignant lesions, and noncancerous pathologies affecting epithelial cells express abnormal MUC1, which is not a self‐antigen but rather an abnormal disease‐associated antigen (DAA). This distinction, which can be made for many known TAAs, has broad implications for the design and acceptance of preventative cancer vaccines.

Url:

https://api.istex.fr/document/D946B4FEC4126C746CBBFB89064A85A64A5C4123/fulltext/pdf

DOI: 10.1111/nyas.12108

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 003377
to stream Istex, to step Curation: 003377
to stream Istex, to step Checkpoint: 000B05
to stream Main, to step Merge: 006103
to stream Main, to step Curation: 005D62

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Preventing cancer by targeting abnormally expressed self‐antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas</title>
<author><name sortKey="Beatty, Pamela L" sort="Beatty, Pamela L" uniqKey="Beatty P" first="Pamela L." last="Beatty">Pamela L. Beatty</name>
</author>
<author><name sortKey="Finn, Olivera J" sort="Finn, Olivera J" uniqKey="Finn O" first="Olivera J." last="Finn">Olivera J. Finn</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:D946B4FEC4126C746CBBFB89064A85A64A5C4123</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1111/nyas.12108</idno>
<idno type="url">https://api.istex.fr/document/D946B4FEC4126C746CBBFB89064A85A64A5C4123/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003377</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">003377</idno>
<idno type="wicri:Area/Istex/Curation">003377</idno>
<idno type="wicri:Area/Istex/Checkpoint">000B05</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000B05</idno>
<idno type="wicri:doubleKey">0077-8923:2013:Beatty P:preventing:cancer:by</idno>
<idno type="wicri:Area/Main/Merge">006103</idno>
<idno type="wicri:Area/Main/Curation">005D62</idno>
<idno type="wicri:Area/Main/Exploration">005D62</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Preventing cancer by targeting abnormally expressed self‐antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas</title>
<author><name sortKey="Beatty, Pamela L" sort="Beatty, Pamela L" uniqKey="Beatty P" first="Pamela L." last="Beatty">Pamela L. Beatty</name>
<affiliation wicri:level="3"><country>États-Unis</country>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
<wicri:orgArea>Department of Immunology, University of Pittsburgh School of Medicine, Pennsylvania</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Finn, Olivera J" sort="Finn, Olivera J" uniqKey="Finn O" first="Olivera J." last="Finn">Olivera J. Finn</name>
<affiliation wicri:level="3"><country>États-Unis</country>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
<wicri:orgArea>Department of Immunology, University of Pittsburgh School of Medicine, Pennsylvania</wicri:orgArea>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Annals of the New York Academy of Sciences</title>
<title level="j" type="alt">ANNALS OF THE NEW YORK ACADEMY OF SCIENCES</title>
<idno type="ISSN">0077-8923</idno>
<idno type="eISSN">1749-6632</idno>
<imprint><biblScope unit="vol">1284</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="52">52</biblScope>
<biblScope unit="page" to="56">56</biblScope>
<biblScope unit="page-count">5</biblScope>
<date type="published" when="2013-05">2013-05</date>
</imprint>
<idno type="ISSN">0077-8923</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0077-8923</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abnormal</term>
<term>Abnormal expression</term>
<term>Abnormal form</term>
<term>Abnormal glycosylation</term>
<term>Abnormal muc1</term>
<term>Abnormal muc1 expression</term>
<term>Acad</term>
<term>Animal models</term>
<term>Apical surface</term>
<term>Beatty</term>
<term>Beatty finn muc1 vaccines</term>
<term>Bile acids</term>
<term>Biomarkers prev</term>
<term>Bowel disease</term>
<term>Cancer epidemiol</term>
<term>Cancer immunoprevention</term>
<term>Cancer patients</term>
<term>Cancer prev</term>
<term>Cancer prevention</term>
<term>Clinical trials</term>
<term>Colon</term>
<term>Colon cancer</term>
<term>Epithelial</term>
<term>Epithelial cells</term>
<term>Finn</term>
<term>Healthy individuals</term>
<term>High risk</term>
<term>Immune</term>
<term>Immune memory</term>
<term>Immune responses</term>
<term>Immune suppression</term>
<term>Immune system</term>
<term>Lesion</term>
<term>Major histocompatibility</term>
<term>Muc1</term>
<term>Muc1 expression</term>
<term>Muc1 vaccine</term>
<term>Muc1 vaccines</term>
<term>Mucin</term>
<term>Nonmalignant conditions</term>
<term>Nonviral cancers</term>
<term>Ovarian cancer</term>
<term>Pancreatic cancer</term>
<term>Peptide backbone</term>
<term>Pittsburgh school</term>
<term>Premalignant</term>
<term>Premalignant disease</term>
<term>Premalignant lesions</term>
<term>Progression</term>
<term>Such vaccines</term>
<term>Taas</term>
<term>Tumor antigens</term>
<term>Tumor growth</term>
<term>Unpublished data</term>
<term>Vaccine</term>
<term>Vntr region</term>
<term>York academy</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Abnormal</term>
<term>Abnormal expression</term>
<term>Abnormal form</term>
<term>Abnormal glycosylation</term>
<term>Abnormal muc1</term>
<term>Abnormal muc1 expression</term>
<term>Acad</term>
<term>Animal models</term>
<term>Apical surface</term>
<term>Beatty</term>
<term>Beatty finn muc1 vaccines</term>
<term>Bile acids</term>
<term>Biomarkers prev</term>
<term>Bowel disease</term>
<term>Cancer epidemiol</term>
<term>Cancer immunoprevention</term>
<term>Cancer patients</term>
<term>Cancer prev</term>
<term>Cancer prevention</term>
<term>Clinical trials</term>
<term>Colon</term>
<term>Colon cancer</term>
<term>Epithelial</term>
<term>Epithelial cells</term>
<term>Finn</term>
<term>Healthy individuals</term>
<term>High risk</term>
<term>Immune</term>
<term>Immune memory</term>
<term>Immune responses</term>
<term>Immune suppression</term>
<term>Immune system</term>
<term>Lesion</term>
<term>Major histocompatibility</term>
<term>Muc1</term>
<term>Muc1 expression</term>
<term>Muc1 vaccine</term>
<term>Muc1 vaccines</term>
<term>Mucin</term>
<term>Nonmalignant conditions</term>
<term>Nonviral cancers</term>
<term>Ovarian cancer</term>
<term>Pancreatic cancer</term>
<term>Peptide backbone</term>
<term>Pittsburgh school</term>
<term>Premalignant</term>
<term>Premalignant disease</term>
<term>Premalignant lesions</term>
<term>Progression</term>
<term>Such vaccines</term>
<term>Taas</term>
<term>Tumor antigens</term>
<term>Tumor growth</term>
<term>Unpublished data</term>
<term>Vaccine</term>
<term>Vntr region</term>
<term>York academy</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">Prophylactic vaccines based on tumor‐associated antigens (TAAs) have elicited concerns due to their potential toxicity. Because TAAs are considered self‐antigens, the prediction is that such vaccines will induce autoimmunity. While this has been observed in melanoma, where an antitumor immune response leads to vitiligo, autoimmunity has almost never been seen following vaccination with numerous other TAAs. We hypothesized that antigen choice determines outcome and have been working to identify TAAs whose expression differs between normal and tumor tissue, and thus could elicit antitumor immunity without autoimmunity. Studies on the epithelial TAA MUC1 have revealed that, compared to MUC1 on normal cells, tumors, premalignant lesions, and noncancerous pathologies affecting epithelial cells express abnormal MUC1, which is not a self‐antigen but rather an abnormal disease‐associated antigen (DAA). This distinction, which can be made for many known TAAs, has broad implications for the design and acceptance of preventative cancer vaccines.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Pennsylvanie</li>
</region>
<settlement><li>Pittsburgh</li>
</settlement>
</list>
<tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Beatty, Pamela L" sort="Beatty, Pamela L" uniqKey="Beatty P" first="Pamela L." last="Beatty">Pamela L. Beatty</name>
</region>
<name sortKey="Finn, Olivera J" sort="Finn, Olivera J" uniqKey="Finn O" first="Olivera J." last="Finn">Olivera J. Finn</name>
<name sortKey="Finn, Olivera J" sort="Finn, Olivera J" uniqKey="Finn O" first="Olivera J." last="Finn">Olivera J. Finn</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005D62 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005D62 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:D946B4FEC4126C746CBBFB89064A85A64A5C4123
   |texte=   Preventing cancer by targeting abnormally expressed self‐antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas
}}

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur Pittsburgh

Preventing cancer by targeting abnormally expressed self‐antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas

Preventing cancer by targeting abnormally expressed self‐antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri